$EVFM
Evofem Biosciences, Inc.

2015 Q2 Form 10-Q Financial Statement

#000156459015004240 Filed on May 14, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.730M $1.940M $1.340M
YoY Change 64.76% 76.36% 61.45%
% of Gross Profit
Research & Development $7.470M $4.701M $1.920M
YoY Change 703.22% 240.63% 12.28%
% of Gross Profit
Depreciation & Amortization $20.00K $0.00 $10.00K
YoY Change 100.0%
% of Gross Profit
Operating Expenses $9.199M $6.638M $3.260M
YoY Change 364.61% 167.13% 28.35%
Operating Profit -$9.199M -$6.638M
YoY Change 167.13%
Interest Expense -$280.0K -$260.0K $360.0K
YoY Change -6.67% -129.55% -244.0%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change
Pretax Income -$9.480M -$6.900M -$2.900M
YoY Change 315.79% 331.25% 3.94%
Income Tax
% Of Pretax Income
Net Earnings -$9.480M -$6.902M -$2.900M
YoY Change 315.79% 330.8% 3.94%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$4.158M -$3.026M -$8.529M
COMMON SHARES
Basic Shares Outstanding 13.67M
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.00M $70.70M $75.90M
YoY Change 447.83% 1625.0%
Cash & Equivalents $62.95M $70.72M $75.95M
Short-Term Investments
Other Short-Term Assets $800.0K $800.0K $900.0K
YoY Change 60.0% 800.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $63.80M $71.48M $76.87M
YoY Change 431.67% 1608.3%
LONG-TERM ASSETS
Property, Plant & Equipment $200.0K $241.0K $24.81K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K
YoY Change
Total Long-Term Assets $400.0K $441.0K $24.81K
YoY Change 300.0%
TOTAL ASSETS
Total Short-Term Assets $63.80M $71.48M $76.87M
Total Long-Term Assets $400.0K $441.0K $24.81K
Total Assets $64.20M $71.92M $76.90M
YoY Change 430.58% 1608.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.000M $1.898M $997.3K
YoY Change 650.0% 66.21%
Accrued Expenses $1.800M $1.591M $912.3K
YoY Change 80.0% 30.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.200M $487.7K $0.00
YoY Change -100.0%
Total Short-Term Liabilities $6.000M $3.976M $1.910M
YoY Change 328.57% 27.31%
LONG-TERM LIABILITIES
Long-Term Debt $8.600M $9.300M $9.741M
YoY Change 120.51%
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $8.600M $9.300M $9.741M
YoY Change 56.36% 342.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.000M $3.976M $1.910M
Total Long-Term Liabilities $8.600M $9.300M $9.741M
Total Liabilities $14.60M $13.28M $11.65M
YoY Change 111.59% 214.88%
SHAREHOLDERS EQUITY
Retained Earnings -$76.58M -$69.67M
YoY Change
Common Stock $135.2M $134.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.60M $58.64M $65.25M
YoY Change
Total Liabilities & Shareholders Equity $64.20M $71.92M $76.90M
YoY Change 430.58% 1608.85%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q4
OPERATING ACTIVITIES
Net Income -$9.480M -$6.902M -$2.900M
YoY Change 315.79% 330.8% 3.94%
Depreciation, Depletion And Amortization $20.00K $0.00 $10.00K
YoY Change 100.0%
Cash From Operating Activities -$7.810M -$4.800M -$3.150M
YoY Change 306.77% 72.66% 42.53%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $226.1K -$10.00K
YoY Change 8537.43%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$200.0K $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$430.0K -$10.00K
YoY Change -116.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 0.000 64.45M
YoY Change -98.98% -100.0% -322350.0%
NET CHANGE
Cash From Operating Activities -7.810M -4.800M -3.150M
Cash From Investing Activities 0.000 -430.0K -10.00K
Cash From Financing Activities 40.00K 0.000 64.45M
Net Change In Cash -7.770M -5.230M 61.29M
YoY Change -490.45% -201.75% -2924.42%
FREE CASH FLOW
Cash From Operating Activities -$7.810M -$4.800M -$3.150M
Capital Expenditures $0.00 $226.1K -$10.00K
Free Cash Flow -$7.810M -$5.026M -$3.140M
YoY Change 306.77% 80.63% 42.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 dei Trading Symbol
TradingSymbol
NEOT
CY2015Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
487738
CY2015Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9300188
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
1366
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
6637989
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
2484968
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6637989
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2484968
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
7455
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
908
CY2015Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
271846
CY2014Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
4186
CY2014Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-886008
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-6902380
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-1602238
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.00
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13671311
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
533544
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3802
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4983
CY2015Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-6139
CY2015Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
46846
CY2014Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
2601
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
299086
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
98083
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-164195
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-12380
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1578915
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-412666
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4803397
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2782865
CY2015Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
200000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
226128
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2618
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-426128
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2618
CY2014Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
117837
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
49400
CY2014Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
7992718
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7924281
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5229525
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5138798
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
Neothetics, Inc.
CY2015Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
200000
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001618835
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13671311
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70717991
CY2014Q4 us-gaap Assets Current
AssetsCurrent
76873289
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 us-gaap Assets Current
AssetsCurrent
71479569
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24809
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1937321
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1101530
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
135219861
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76577092
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1909589
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75947516
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3976242
CY2014Q4 us-gaap Assets
Assets
76898098
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
761578
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1590877
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
925773
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
912320
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
240996
CY2015Q1 us-gaap Assets
Assets
71920565
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9741080
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1897627
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
1366
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
997269
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9502805
CY2014Q1 us-gaap Interest Paid
InterestPaid
2397
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13671311
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
58644135
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71920565
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13671311
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4700668
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4364007
CY2015Q1 us-gaap Interest Paid
InterestPaid
225000
CY2015Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held.</p></div>
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p></div>
CY2015Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2007-02-01
CY2015Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2015Q1 neot Lease Expiration Period
LeaseExpirationPeriod
2020-03
CY2015Q1 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2014Q1 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1485060
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9235979
CY2015Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
281606
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
153460
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
40610
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
128651
CY2015Q1 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.090
CY2015Q1 us-gaap Debt Instrument Description Of Variable Rate Basis
DebtInstrumentDescriptionOfVariableRateBasis
The loan bears interest equal to the greater of either 9.0%, plus the Prime Rate as reported in The Wall Street Journal, less 3.25% or 9.0%
CY2015Q1 us-gaap Debt Instrument Payment Terms
DebtInstrumentPaymentTerms
Interest only is due and payable through January 2016, with principal and interest payments due commencing February 2016
CY2015Q1 neot Debt Instrument Maturity Month And Year
DebtInstrumentMaturityMonthAndYear
2018-01
CY2015Q1 neot Debt Instrument End Of Term Charge
DebtInstrumentEndOfTermCharge
300000
CY2015Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
687500
CY2015Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
3575471
CY2015Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
3815968
CY2015Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
4275001
CY2015Q1 us-gaap Long Term Debt
LongTermDebt
12353940
CY2015Q1 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
2353941
CY2015Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
212073
CY2015Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
71257
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.00
CY2015Q1 neot Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P8Y
CY2015Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-6.1
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.68
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.79
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.46
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1198830
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
214973
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1413803
CY2015Q1 neot Share Based Compensation Expense In Research And Development Expense
ShareBasedCompensationExpenseInResearchAndDevelopmentExpense
205310
CY2014Q1 neot Share Based Compensation Expense In Research And Development Expense
ShareBasedCompensationExpenseInResearchAndDevelopmentExpense
56430
CY2015Q1 neot Share Based Compensation General And Administrative Expense
ShareBasedCompensationGeneralAndAdministrativeExpense
93776
CY2014Q1 neot Share Based Compensation General And Administrative Expense
ShareBasedCompensationGeneralAndAdministrativeExpense
41653
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
299086
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
98083
CY2015Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3124398
CY2014Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9491487
CY2015Q1 neot Noncancelable Operating Lease Agreement Date
NoncancelableOperatingLeaseAgreementDate
2015-01-20
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
299967
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
399957
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
399957
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
399957
CY2015Q1 neot Operating Leases Future Minimum Payments Due After Year Four And Thereafter
OperatingLeasesFutureMinimumPaymentsDueAfterYearFourAndThereafter
499946
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1999784

Files In Submission

Name View Source Status
0001564590-15-004240-index-headers.html Edgar Link pending
0001564590-15-004240-index.html Edgar Link pending
0001564590-15-004240.txt Edgar Link pending
0001564590-15-004240-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
neot-10q_20150331.htm Edgar Link pending
neot-20150331.xml Edgar Link completed
neot-20150331.xsd Edgar Link pending
neot-20150331_cal.xml Edgar Link unprocessable
neot-20150331_def.xml Edgar Link unprocessable
neot-20150331_lab.xml Edgar Link unprocessable
neot-20150331_pre.xml Edgar Link unprocessable
neot-ex311_201503316.htm Edgar Link pending
neot-ex312_201503317.htm Edgar Link pending
neot-ex321_201503318.htm Edgar Link pending
neot-ex322_201503319.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending